Výsledky vyhledávání - "multiple sclerosis-drug therapy"

Akademický článek

Memory B Cells in Multiple Sclerosis: Emerging Players in Disease Pathogenesis

Autor: Krista D. DiSano, Francesca Gilli, Andrew R. Pachner

Publikováno v: Frontiers in Immunology, Vol 12 (2021)

Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system. Once thought to be primarily driven by T cells, B cells are emerging as central players in MS immunopathogenesis. Interest in multiple B cell phenotypes i

Externí odkaz: https://doaj.org/article/9e9cf9c7f9d042b18df4060c50d31ea3

Zobrazit plný text záznamu

Akademický článek

Management of MS Patients Treated With Daclizumab – a Case Series of 267 Patients

Autor: Paulus S. Rommer, Klaus Berger, David Ellenberger, Firas Fneish, Alexandra Simbrich, Alexander Stahmann, Uwe K. Zettl

Publikováno v: Frontiers in Neurology, Vol 11 (2020)

Daclizumab was approved by the FDA and the EMA in 2016 for the treatment of relapsing forms of multiple sclerosis (MS). Cases of severe inflammatory brain disease with fatal outcome led to the withdrawal of approval in Europe and the US on March 2, 2

Externí odkaz: https://doaj.org/article/e6c33d9b2b4b49d19dcdf78faaefe9d2

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis:A Danish nationwide study

Autor: Per Soelberg Sorensen, Luigi Pontieri, Hanna Joensen, Alex Heick, Peter Vestergaard Rasmussen, Jakob Schäfer, Rikke Ratzer, Caroline Ellinore Pihl, Finn Sellebjerg, Melinda Magyari

Publikováno v: Sorensen, P S, Pontieri, L, Joensen, H, Heick, A, Rasmussen, P V, Schäfer, J, Ratzer, R, Pihl, C E, Sellebjerg, F & Magyari, M 2023, ' Real-world experience of cladribine treatment in relapsing-remitting multiple sclerosis : A Danish nationwide study ', Multiple Sclerosis and Related Disorders, vol. 70, 104491 . https://doi.org/10.1016/j.msard.2022.104491

BACKGROUND: Cladribine is a nucleoside analogue interfering with synthesis and repair of DNA. Treatment with cladribine leads to a preferential reduction in lymphocytes, resulting in profound depletion of B-cells with a rapid recovery of naïve B-cel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ce0c113b0169309b5c87eec38d5c5b3
https://vbn.aau.dk/ws/files/514548645/S_rensen_et_al._2022_Real_world_experience_of_cladribine_treatment_in_relapsing_remitting_multiple_sclerosis.pdf

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Multiple sclerosis clinical decision support system based on projection to reference datasets

Autor: Chadia Ed‐driouch, Florent Chéneau, Françoise Simon, Guillaume Pasquier, Benoit Combès, Anne Kerbrat, Emmanuelle Le Page, Sophie Limou, Nicolas Vince, David‐Axel Laplaud, Franck Mars, Cédric Dumas, Gilles Edan, Pierre‐Antoine Gourraud

Publikováno v: Annals of Clinical and Translational Neurology
Annals of Clinical and Translational Neurology, 2022, 9 (12), pp.1863-1873. ⟨10.1002/acn3.51649⟩

International audience; Objective: Multiple sclerosis (MS) is a multifactorial disease with increasingly complicated management. Our objective is to use on-demand computational power to address the challenges of dynamically managing MS.Methods: A pha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0344e51453a7dc5208d4f2246e8cc8ac
https://pubmed.ncbi.nlm.nih.gov/36412095

Zobrazit plný text záznamu

Plný text ve formátu HTML

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

Autor: Lefort, M, Sharmin, S, Andersen, J B, Vukusic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, De Sèze, J, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun-Frenay, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Maurousset, A, Ben Nasr, H, Hankiewicz, K, Pottier, C, Maubeuge, N, Dimitri-Boulos, D, Nifle, C, Laplaud, D A, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Eichau, S, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand'Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Maimone, D, Skibina, O, Buzzard, K, Van der Walt, A, Karabudak, R, Van Wijmeersch, B, Csepany, T, Spitaleri, D, Vucic, S, Koch-Henriksen, N, Sellebjerg, F, Soerensen, P S, Hilt Christensen, C. C., Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Butzkueven, H, Magyari, M, Kalincik, T, Leray, E

Publikováno v: Lefort, M, Sharmin, S, Andersen, J B, Vukusic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, De Sèze, J, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun-Frenay, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Maurousset, A, Ben Nasr, H, Hankiewicz, K, Pottier, C, Maubeuge, N, Dimitri-Boulos, D, Nifle, C, Laplaud, D A, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Eichau, S, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand’Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Maimone, D, Skibina, O, Buzzard, K, Van der Walt, A, Karabudak, R, Van Wijmeersch, B, Csepany, T, Spitaleri, D, Vucic, S, Koch-Henriksen, N, Sellebjerg, F, Soerensen, P S, Hilt Christensen, C C, Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Butzkueven, H, Magyari, M, Kalincik, T & Leray, E 2022, ' Impact of methodological choices in comparative effectiveness studies : application in natalizumab versus fingolimod comparison among patients with multiple sclerosis ', BMC Medical Research Methodology, vol. 22, no. 1, 155 . https://doi.org/10.1186/s12874-022-01623-8
BMC Medical Research Methodology
BMC Medical Research Methodology, 2022, 22 (1), pp.155. ⟨10.1186/s12874-022-01623-8⟩
BMC Medical Research Methodology, BioMed Central, 2022, 22 (1), pp.155. ⟨10.1186/s12874-022-01623-8⟩
Lefort, M, Sharmin, S, Andersen, J B, Vukusic, S, Casey, R, Debouverie, M, Edan, G, Ciron, J, Ruet, A, De Sèze, J, Maillart, E, Zephir, H, Labauge, P, Defer, G, Lebrun-Frenay, C, Moreau, T, Berger, E, Clavelou, P, Pelletier, J, Stankoff, B, Gout, O, Thouvenot, E, Heinzlef, O, Al-Khedr, A, Bourre, B, Casez, O, Cabre, P, Montcuquet, A, Wahab, A, Camdessanché, J P, Maurousset, A, Ben Nasr, H, Hankiewicz, K, Pottier, C, Maubeuge, N, Dimitri-Boulos, D, Nifle, C, Laplaud, D A, Horakova, D, Havrdova, E K, Alroughani, R, Izquierdo, G, Eichau, S, Ozakbas, S, Patti, F, Onofrj, M, Lugaresi, A, Terzi, M, Grammond, P, Grand'Maison, F, Yamout, B, Prat, A, Girard, M, Duquette, P, Boz, C, Trojano, M, McCombe, P, Slee, M, Lechner-Scott, J, Turkoglu, R, Sola, P, Ferraro, D, Granella, F, Shaygannejad, V, Prevost, J, Maimone, D, Skibina, O, Buzzard, K, Van der Walt, A, Karabudak, R, Van Wijmeersch, B, Csepany, T, Spitaleri, D, Vucic, S, Koch-Henriksen, N, Sellebjerg, F, Soerensen, P S, Hilt Christensen, C C, Rasmussen, P V, Jensen, M B, Frederiksen, J L, Bramow, S, Mathiesen, H K, Schreiber, K I, Butzkueven, H, Magyari, M, Kalincik, T & Leray, E 2022, ' Impact of methodological choices in comparative effectiveness studies : application in natalizumab versus fingolimod comparison among patients with multiple sclerosis ', BMC Medical Research Methodology, vol. 22, no. 1, 155 . https://doi.org/10.1186/s12874-022-01623-8

Background Natalizumab and fingolimod are used as high-efficacy treatments in relapsing-remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different methods to control treatment in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b76c9aa3b89340f07462e048e392906e
https://avesis.deu.edu.tr/publication/details/fef052b9-7e13-4a9f-b86e-a900c3dd0924/oai

Zobrazit plný text záznamu

Long-Term Effects of Alemtuzumab on CD4+ Lymphocytes in Multiple Sclerosis Patients: A 72-Month Follow-Up

Autor: Simona Rolla, Stefania Federica De Mercanti, Valentina Bardina, Alessandro Maglione, Daniela Taverna, Francesco Novelli, Eleonora Cocco, Anton Vladic, Mario Habek, Ivan Adamec, Pietro Osvaldo Luigi Annovazzi, Dana Horakova, Marinella Clerico

IntroductionAlemtuzumab is highly effective in the treatment of patients with relapsing multiple sclerosis (PwRMS) and selectively targets the CD52 antigen, with a consequent profound lymphopenia, particularly of CD4+ T lymphocytes. However, the immu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17f35e4f26c4be7068d7fce3c4c90ad0
https://doi.org/10.3389/fimmu.2022.818325

Zobrazit plný text záznamu

Immunomodifying and neuroprotective effects of noscapine

Publikováno v: Chemico-Biological Interactions. 352

Noscapine is a phthalide isoquinoline alkaloid with antitussive activity. Noscapine protects oligodendroglia from ischemic and chemical injury, binds to bitter taste receptors, antagonizes the bradykinin and histaminergic systems, which may be of ben

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od________83::7eda232dee01c546a75cc72003b632b6
https://doi.org/10.1016/j.cbi.2021.109794

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání